Jeong Kyeong Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jeong Kyeong Lee has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Chaiheon Lee
Department of Chemistry, School of Natural Science, Ulsan National Institute of Science and Technology (UNIST), Ulsan 44919, Republic of Korea
2 shared publications - Seungjin Na
Korea Basic Science Institute
2 shared publications - Tae-Hyuk Kwon
Ulsan National Institute of Science and Technology
2 shared publications Byeong Gyu Kim
Center for Genomic Integrity, Institute for Basic Science, Ulsan, 44919, Korea
1 shared publication- Byong Chul Yoo
Department of Integrative Biotechnology Sungkyunkwan University Suwon Republic of Korea
1 shared publication Chae Gyu Lee
Department of Chemistry, School of Natural Science, Ulsan National Institute of Science and Technology (UNIST), Ulsan, Republic of Korea
1 shared publication
Latest Publications
- Open Access
Water oxidation-driven histidine dioxidation enables probe-free proximity labeling
Photocatalytic proximity labeling (photo-PL) has emerged as a powerful tool for spatial proteomics in subcellular compartments. However, many photo-PL toolboxes rely on singlet oxygen ( 1 O 2 ) to generate highly unstable endoperoxide intermediates that must be trapped immediately by high concentrations of exogenous probes. This constraint can bias spatial proteome coverage, particularly in dynamic and heterogeneous compartments such as endosomes and exosomes, where probe accessibility is intrinsically nonuniform. Here, we develop IDM, an organic photocatalyst that generates hydroxyl (•OH) and superoxide (O •− ) radicals via water oxidation instead of 1 O , enabling a synergistic dual-radical mechanism for probe-free proximal protein mapping in live cells (PF-Map). The resulting radicals dioxidize proximal histidine residues into a persistent dioxidized state (His-2O) that is thermodynamically stabilized as lactam tautomers, which remain electrophilic and chemically addressable after cell lysis. By decoupling histidine oxidation from live□cell probe capture, PF□Map can minimize spatial bias arising from heterogeneous probe distribution. Applying PF□Map to intracellular vesicle trafficking, we find that both PF□Map and a probe□dependent workflow (PD□Map) robustly identify exosome markers, whereas PF□Map additionally reveals a hidden vesicle trafficking–related subproteome that PD-Map underestimated. Together, we establish a minimally biased photocatalytic strategy for spatial protein mapping in complex biological systems. Graphical
Open AccessWater oxidation-driven histidine dioxidation enables probe-free proximity labeling
Photocatalytic proximity labeling (photo-PL) has emerged as a powerful tool for spatial proteomics in subcellular compartments. However, many photo-PL toolboxes rely on singlet oxygen ( 1 O 2 ) to generate highly unstable endoperoxide intermediates that must be trapped immediately by high concentrations of exogenous probes. This constraint can bias spatial proteome coverage, particularly in dynamic and heterogeneous compartments such as endosomes and exosomes, where probe accessibility is intrinsically nonuniform. Here, we develop IDM, an organic photocatalyst that generates hydroxyl (•OH) and superoxide (O •− ) radicals via water oxidation instead of 1 O , enabling a synergistic dual-radical mechanism for probe-free proximal protein mapping in live cells (PF-Map). The resulting radicals dioxidize proximal histidine residues into a persistent dioxidized state (His-2O) that is thermodynamically stabilized as lactam tautomers, which remain electrophilic and chemically addressable after cell lysis. By decoupling histidine oxidation from live□cell probe capture, PF□Map can minimize spatial bias arising from heterogeneous probe distribution. Applying PF□Map to intracellular vesicle trafficking, we find that both PF□Map and a probe□dependent workflow (PD□Map) robustly identify exosome markers, whereas PF□Map additionally reveals a hidden vesicle trafficking–related subproteome that PD-Map underestimated. Together, we establish a minimally biased photocatalytic strategy for spatial protein mapping in complex biological systems. Graphical
- Open Access
- 13 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Oxidative photocatalysis on membranes triggers non-canonical pyroptosis
Intracellular membranes composing organelles of eukaryotes include membrane proteins playing crucial roles in physiological functions. However, a comprehensive understanding of the cellular responses triggered by intracellular membrane-focused oxidative stress remains elusive. Herein, we report an amphiphilic photocatalyst localised in intracellular membranes to damage membrane proteins oxidatively, resulting in non-canonical pyroptosis. Our developed photocatalysis generates hydroxyl radicals and hydrogen peroxides via water oxidation, which is accelerated under hypoxia. Single-molecule magnetic tweezers reveal that photocatalysis-induced oxidation markedly destabilised membrane protein folding. In cell environment, label-free quantification reveals that oxidative damage occurs primarily in membrane proteins related to protein quality control, thereby aggravating mitochondrial and endoplasmic reticulum stress and inducing lytic cell death. Notably, the photocatalysis activates non-canonical inflammasome caspases, resulting in gasdermin D cleavage to its pore-forming fragment and subsequent pyroptosis. These findings suggest that the oxidation of intracellular membrane proteins triggers non-canonical pyroptosis.
- 13 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-16
Open AccessOxidative photocatalysis on membranes triggers non-canonical pyroptosis
Intracellular membranes composing organelles of eukaryotes include membrane proteins playing crucial roles in physiological functions. However, a comprehensive understanding of the cellular responses triggered by intracellular membrane-focused oxidative stress remains elusive. Herein, we report an amphiphilic photocatalyst localised in intracellular membranes to damage membrane proteins oxidatively, resulting in non-canonical pyroptosis. Our developed photocatalysis generates hydroxyl radicals and hydrogen peroxides via water oxidation, which is accelerated under hypoxia. Single-molecule magnetic tweezers reveal that photocatalysis-induced oxidation markedly destabilised membrane protein folding. In cell environment, label-free quantification reveals that oxidative damage occurs primarily in membrane proteins related to protein quality control, thereby aggravating mitochondrial and endoplasmic reticulum stress and inducing lytic cell death. Notably, the photocatalysis activates non-canonical inflammasome caspases, resulting in gasdermin D cleavage to its pore-forming fragment and subsequent pyroptosis. These findings suggest that the oxidation of intracellular membrane proteins triggers non-canonical pyroptosis.
- Open Access
- 19 April 2017
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (suppl_3) , iii5
OS03.2 CSF metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients having high risk for leptomeningeal metastasis from brain metastasis or brain tumors
Introduction: Leptomeningeal carcinomatosis (LMC) is terminal stage cancer disease that resist to conventional chemo-/radiation therapy and quickly devastating patient’s performance. Early diagnosis is necessary for challenging this formidable disease. However, cerebrospinal (CSF) cytology frequently results in false negative. Metabolic profile reveals tumor environment and has been tried to diagnose cancers at early stage. Here, we analyzed the CSF metabolome profiles and evaluate if they can be used differentiate patient with LMC from patients without LMC but having a risk factor for developing LMC. Materials and Methods: We prospectively collected CSF from patients at time of spinal anesthesia, craniotomy, and CSF drainage after permission from both patient and institutional review board. CSF archive was consisted of 6 different groups; 1) group 1a; CNS tumor free with systemic cancer, 2) group 1b; no tumor, 3) group 2; LMC, 3) group 3; brain metastasis, 4) group 4; brain tumor other than brain metastasis, 5) group 5; CNS inflammatory disease without cancer. From the CSF archive, 199 samples were selected by following criteria; 1) in LMC group, CSF cytology proven at the time of sampling, 2) in the high risk group of brain metastasis and brain tumor, CSF cytology was proven to be negative and followed up at least 6 months. All metabolites in CSF samples collected from 6 different groups were detected as low-mass ions (LMIs) using triple-TOF mass spectrometry. Principal component analysis-based discriminant analysis (PCA-DA) and two search algorithms were used to select LMIs for differentiating healthy controls from patient group or for separating patients with LMC from other patient groups. Results: A total of 10,905 low mass ion was evaluated thorough PCA-DA and can define group 2 of LMC at a sensitivity of 85% and specificity of 91%. Group 1b of no tumor can be differentiated with other groups at sensitivity of 83% and specificity of 84%. After selecting 33 low mass ion including indoleacrylic acid through algorithm 2, CSF metabolomics profile showed sensitivity of 100% and specificity of 92% for discriminating group 1b from others. After selecting 21 low mass ion including diacetyl spermine, CSF metabolomics profile can differentiate LMC patients from the high risk group of brain metastases and brain tumors at both sensitivity and specificity of 100%. Conclusion: CSF metabolite profiles can differentiate these 6 groups of different cancer status. We evaluate these metabolic analysis can diagnose LMC and exclude the high risk group at an accuracy of 100%. We expect CSF metabolic profiles can replace CSF cytology for the diagnosis of LMC and in the future trial, can be used to differentiate false positive such as postoperative CSF cytology from truly proliferating LMC.
- 19 April 2017
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 19 (suppl_3) , iii5
Open AccessOS03.2 CSF metabolomic profiles can discriminate patients with leptomeningeal carcinomatosis from patients having high risk for leptomeningeal metastasis from brain metastasis or brain tumors
Introduction: Leptomeningeal carcinomatosis (LMC) is terminal stage cancer disease that resist to conventional chemo-/radiation therapy and quickly devastating patient’s performance. Early diagnosis is necessary for challenging this formidable disease. However, cerebrospinal (CSF) cytology frequently results in false negative. Metabolic profile reveals tumor environment and has been tried to diagnose cancers at early stage. Here, we analyzed the CSF metabolome profiles and evaluate if they can be used differentiate patient with LMC from patients without LMC but having a risk factor for developing LMC. Materials and Methods: We prospectively collected CSF from patients at time of spinal anesthesia, craniotomy, and CSF drainage after permission from both patient and institutional review board. CSF archive was consisted of 6 different groups; 1) group 1a; CNS tumor free with systemic cancer, 2) group 1b; no tumor, 3) group 2; LMC, 3) group 3; brain metastasis, 4) group 4; brain tumor other than brain metastasis, 5) group 5; CNS inflammatory disease without cancer. From the CSF archive, 199 samples were selected by following criteria; 1) in LMC group, CSF cytology proven at the time of sampling, 2) in the high risk group of brain metastasis and brain tumor, CSF cytology was proven to be negative and followed up at least 6 months. All metabolites in CSF samples collected from 6 different groups were detected as low-mass ions (LMIs) using triple-TOF mass spectrometry. Principal component analysis-based discriminant analysis (PCA-DA) and two search algorithms were used to select LMIs for differentiating healthy controls from patient group or for separating patients with LMC from other patient groups. Results: A total of 10,905 low mass ion was evaluated thorough PCA-DA and can define group 2 of LMC at a sensitivity of 85% and specificity of 91%. Group 1b of no tumor can be differentiated with other groups at sensitivity of 83% and specificity of 84%. After selecting 33 low mass ion including indoleacrylic acid through algorithm 2, CSF metabolomics profile showed sensitivity of 100% and specificity of 92% for discriminating group 1b from others. After selecting 21 low mass ion including diacetyl spermine, CSF metabolomics profile can differentiate LMC patients from the high risk group of brain metastases and brain tumors at both sensitivity and specificity of 100%. Conclusion: CSF metabolite profiles can differentiate these 6 groups of different cancer status. We evaluate these metabolic analysis can diagnose LMC and exclude the high risk group at an accuracy of 100%. We expect CSF metabolic profiles can replace CSF cytology for the diagnosis of LMC and in the future trial, can be used to differentiate false positive such as postoperative CSF cytology from truly proliferating LMC.